Celebi N - Search Results

1

Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.

Tashan E, Karakucuk A, Celebi N. Tashan E, et al. Among authors: celebi n. AAPS PharmSciTech. 2020 Apr 15;21(3):115. doi: 10.1208/s12249-020-01653-9. AAPS PharmSciTech. 2020. PMID: 32296987

2

Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.

Karakucuk A, Celebi N, Teksin ZS. Karakucuk A, et al. Among authors: celebi n. Eur J Pharm Sci. 2016 Dec 1;95:111-121. doi: 10.1016/j.ejps.2016.05.010. Epub 2016 May 13. Eur J Pharm Sci. 2016. PMID: 27181836

3

Development of Interleukin-2 Loaded Chitosan-Based Nanogels Using Artificial Neural Networks and Investigating the Effects on Wound Healing in Rats.

Aslan C, Çelebi N, Değim IT, Atak A, Özer Ç. Aslan C, et al. Among authors: celebi n. AAPS PharmSciTech. 2017 May;18(4):1019-1030. doi: 10.1208/s12249-016-0662-4. Epub 2016 Nov 16. AAPS PharmSciTech. 2017. PMID: 27853994

4

New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system.

Gülbağ S, Yılmaz Usta D, Gültekin HE, Oktay AN, Demirtaş Ö, Karaküçük A, Çelebi N. Gülbağ S, et al. Among authors: celebi n. Pharm Dev Technol. 2018 Jun;23(5):512-519. doi: 10.1080/10837450.2017.1345941. Epub 2017 Jul 18. Pharm Dev Technol. 2018. PMID: 28657404

5

Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.

Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. Oktay AN, et al. Among authors: celebi n. Eur J Pharm Sci. 2018 Sep 15;122:254-263. doi: 10.1016/j.ejps.2018.07.009. Epub 2018 Jul 4. Eur J Pharm Sci. 2018. PMID: 29981401

6

Evaluation of improved oral bioavailability of ritonavir nanosuspension.

Karakucuk A, Teksin ZS, Eroglu H, Celebi N. Karakucuk A, et al. Among authors: celebi n. Eur J Pharm Sci. 2019 Apr 1;131:153-158. doi: 10.1016/j.ejps.2019.02.028. Epub 2019 Feb 18. Eur J Pharm Sci. 2019. PMID: 30790704

7

Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.

Tashan E, Karakucuk A, Celebi N. Tashan E, et al. Among authors: celebi n. AAPS PharmSciTech. 2020 May 19;21(5):144. doi: 10.1208/s12249-020-01703-2. AAPS PharmSciTech. 2020. PMID: 32430673

8

Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.

Karakucuk A, Celebi N. Karakucuk A, et al. Among authors: celebi n. Pharm Res. 2020 May 31;37(6):111. doi: 10.1007/s11095-020-02815-x. Pharm Res. 2020. PMID: 32476048

9

Etodolac nanosuspension based gel for enhanced dermal delivery: in vitro and in vivo evaluation.

Karakucuk A, Tort S, Han S, Oktay AN, Celebi N. Karakucuk A, et al. Among authors: celebi n. J Microencapsul. 2021 Jun;38(4):218-232. doi: 10.1080/02652048.2021.1895344. Epub 2021 Mar 23. J Microencapsul. 2021. PMID: 33752553

10

In Vitro Caco-2 Cell Permeability Studies of Ziprasidone Hydrochloride Monohydrate Nanocrystals.

Karaküçük A, Taşhan E, Öztürk N, Çelebi N. Karaküçük A, et al. Among authors: celebi n. Turk J Pharm Sci. 2021 Apr 20;18(2):223-227. doi: 10.4274/tjps.galenos.2020.67366. Turk J Pharm Sci. 2021. PMID: 33902264 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters